Shopping Cart
Remove All
Your shopping cart is currently empty
JYQ-164 is a small molecule inhibitor targeting human Parkinson's disease protein 7 (PARK7/DJ-1). It functions by covalently and selectively targeting the critical residue Cys106 of PARK7, exhibiting an IC50 of 21 nM. JYQ-164 demonstrates five times greater inhibitory potency against PARK7 compared to the previously reported inhibitor, JYQ-88. It is applicable for research in Parkinson's disease and cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | JYQ-164 is a small molecule inhibitor targeting human Parkinson's disease protein 7 (PARK7/DJ-1). It functions by covalently and selectively targeting the critical residue Cys106 of PARK7, exhibiting an IC50 of 21 nM. JYQ-164 demonstrates five times greater inhibitory potency against PARK7 compared to the previously reported inhibitor, JYQ-88. It is applicable for research in Parkinson's disease and cancer. |
| Targets&IC50 | PARK7:21 nM |
| Formula | C23H26N6O5S2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.